Part,  Chapter, Paragraph

  1    I,     2.  5        |           are flexibly deployed over multiple tasks. Some contractual
  2   II,     5.  1.  1    |        cardio-vascular diseases.~ ~· Multiple Sclerosis~Multiple Sclerosis
  3   II,     5.  1.  1    |                   Multiple Sclerosis~Multiple Sclerosis is a complex multifactorial
  4   II,     5.  2.  3    |        different coding practice and multiple hospital admissions for
  5   II,     5.  2.  3    |        different coding practice and multiple hospital admissions for
  6   II,     5.  2.  3    |              various factors such as multiple hospital admissions for
  7   II,     5.  2.  6    |             primary screenees of the Multiple Risk Factor Intervention
  8   II,     5.  5.  3    |     Longitudinal Study on Ageing~MSA~Multiple System Atrophy~PD~Parkinson’
  9   II,     5.  5.  3    |               2007): Associations of multiple domains of self-esteem with
 10   II,     5.  5.  3    |        disease frequency trends from multiple surveys. ~Prevalence rates
 11   II,     5.  5.  3    |           epilepsy population. Thus, multiple sources of cases must be
 12   II,     5.  5.  3    |                              5.5.3.5 Multiple sclerosis~ ~
 13   II,     5.  5.  3    |              5.3.5.1. Introduction~ ~Multiple sclerosis (MS) is a chronic
 14   II,     5.  5.  3    |       manifests itself with signs of multiple neurological dysfunctions (
 15   II,     5.  5.  3    |          examples follow. The Danish Multiple Sclerosis Registry (DMSR)
 16   II,     5.  5.  3    |         information on MS cases from multiple sources, including the National
 17   II,     5.  5.  3    |            to be a valuable tool for multiple assessments of MS epidemiological
 18   II,     5.  5.  3    |            The European Database for Multiple Sclerosis (EDMUS) has been
 19   II,     5.  5.  3    |        European Concerted Action for Multiple Sclerosis funded by the
 20   II,     5.  5.  3    |               The Norwegian National Multiple Sclerosis Registry was established
 21   II,     5.  5.  3    |             in 2001 at the Norwegian Multiple Sclerosis National Competence
 22   II,     5.  5.  3    |             5.5.3.5.1. Prevalence of Multiple Sclerosis in selected EUGLOREH
 23   II,     5.  5.  3    |          Prevalence (per 100 000) of Multiple Sclerosis in selected EUGLOREH
 24   II,     5.  5.  3    |          Prevalence (per 100 000) of Multiple Sclerosis in selected EUGLOREH
 25   II,     5.  5.  3    |      Incidence (per 100 000/year) of Multiple Sclerosis in Europe~ ~ ~
 26   II,     5.  5.  3    |             rate was 2.6 in 197488. Multiple assessments carried out
 27   II,     5.  5.  3    |         national health care system, multiple large population-based assessments
 28   II,     5.  5.  3    |             epidemiological methods, multiple assessments and increased
 29   II,     5.  5.  3    |             5.5.3.5.5. Proportion of Multiple Sclerosis patients by disease
 30   II,     5.  5.  3    |             5.5.3.5.6. Proportion of Multiple Sclerosis patients by disease
 31   II,     5.  5.  3    |            and incidence rates where multiple assessments have been carried
 32   II,     5.  5.  3    |            methodology in time.~When multiple regression models were used
 33   II,     5.  5.  3    |        Directive on EU citizens with multiple sclerosis has not yet been
 34   II,     5.  5.  3    |      analysed; however, the onset of multiple sclerosis often occurs at
 35   II,     5.  5.  3    |        treatment towards people with multiple sclerosis within the European
 36   II,     5.  5.  3    |             by a British person with Multiple Sclerosis, Louise McVay.
 37   II,     5.  5.  3    |            supported by the European Multiple Sclerosis Platform and all
 38   II,     5.  5.  3    |        Sclerosis Platform and all EU Multiple Sclerosis Societies. Health
 39   II,     5.  5.  3    |        services in the management of Multiple Sclerosis;~· A shared agenda
 40   II,     5.  5.  3    |            Code of Good Practice” on Multiple Sclerosis and its reference
 41   II,     5.  5.  3    |           Code~· The European Map of Multiple Sclerosis, (ww g)~The European
 42   II,     5.  5.  3    |             care of MS patients. The multiple sclerosis therapy consensus
 43   II,     5.  5.  3    |             Services for People with Multiple Sclerosis in Europe by the
 44   II,     5.  5.  3    |            in Europe by the European Multiple Sclerosis Platform and RIMS,
 45   II,     5.  5.  3    |              RIMS, Rehabilitation in Multiple Sclerosis (Battaglia et
 46   II,     5.  5.  3    |            among foremost experts in Multiple Sclerosis Rehabilitation
 47   II,     5.  5.  3    |        people severely affected with multiple sclerosis ( Haffenden et
 48   II,     5.  5.  3    |              constitute the European Multiple Sclerosis Platform (EMSP).
 49   II,     5.  5.  3    |             international level, the Multiple Sclerosis International
 50   II,     5.  5.  3(26)|        treatment made to people with multiple sclerosis within the European
 51   II,     5.  5.  3    |              project entitled MS-ID (Multiple SclerosisInformation
 52   II,     5.  5.  3    |              EU citizens affected by Multiple Sclerosis (MS). It will
 53   II,     5.  5.  3    |       prevalence and epidemiology of multiple sclerosis in Europe; good
 54   II,     5.  5.  3    |            Pascu I (2004): Report of multiple sclerosis centers. Cephalalgia
 55   II,     5.  5.  3    |            Services for Persons with Multiple Sclerosis in Europe~Baumhackl
 56   II,     5.  5.  3    |             al (2002): Prevalence of multiple sclerosis in Austria. Results
 57   II,     5.  5.  3    |              Epidemiologic survey of multiple sclerosis in Mures County,
 58   II,     5.  5.  3    |             2001): The prevalence of multiple sclerosis, distribution
 59   II,     5.  5.  3    |         natural history of untreated multiple sclerosis in Iceland. A
 60   II,     5.  5.  3    |              E, Vela L et al (1998): Multiple sclerosis in Móstoles, central
 61   II,     5.  5.  3    |        Berkowicz T (2004): Report of multiple sclerosis center in Lodz.
 62   II,     5.  5.  3    |               1995): Epidemiology of multiple sclerosis in Russia and
 63   II,     5.  5.  3    |              71-76.~Boiko AN (1994): Multiple sclerosis prevalence in
 64   II,     5.  5.  3    |          Firnhaber W, Lauer K (eds): Multiple Sclerosis in Europe: An
 65   II,     5.  5.  3    |            Survival of patients with multiple sclerosis in Denmark: a
 66   II,     5.  5.  3    |              in Damish patients with multiple sclerosis. Brain 127:844-
 67   II,     5.  5.  3    |         Celius EG, Vandvik B (2001): Multiple sclerosis in Oslo, Norway:
 68   II,     5.  5.  3    |              a European database for multiple sclerosis. J Neurol Neurosurg
 69   II,     5.  5.  3    |             Establishment and use of multiple sclerosis registersEDMUS.
 70   II,     5.  5.  3    |         progression of disability in multiple sclerosis. N Engl J Med
 71   II,     5.  5.  3    |           irreversible disability in multiple sclerosis: an amnesic process.
 72   II,     5.  5.  3    |          Nyland H, Midgard R (2004): Multiple sclerosis in Nord-Trøndelag
 73   II,     5.  5.  3    |             2006): The prevalence of multiple sclerosis in the District
 74   II,     5.  5.  3    |             de Bono A, et al (2002): Multiple sclerosis in Malta in 1999:
 75   II,     5.  5.  3    |            1998). Natural history of multiple sclerosis. In: Compston
 76   II,     5.  5.  3    |          Compston A (ed). McAlpine’s Multiple Sclerosis, 3rd edition.
 77   II,     5.  5.  3    |            Environmental factors and multiple sclerosis. Lancet 7;268-
 78   II,     5.  5.  3    |             G (2004). Mortality from multiple sclerosis in Austria 1970–
 79   II,     5.  5.  3    |              al (2004): Diagnosis of multiple sclerosis: comparison of
 80   II,     5.  5.  3    |             W, Lauer K (eds) (1994): Multiple Sclerosis in Europe: An
 81   II,     5.  5.  3    |            Treatment and Research in Multiple Sclerosis. Prague, Czech Republic
 82   II,     5.  5.  3    |             1999): The prevalence of multiple sclerosis in Tayside, Scotland:
 83   II,     5.  5.  3    |             1998): The prevalence of multiple sclerosis in the Leeds Health
 84   II,     5.  5.  3    |          prevalence and mortality of multiple sclerosis in Leeds. J Neurol
 85   II,     5.  5.  3    |               Symptomatic fatigue in multiple sclerosis. Arch Phys Med
 86   II,     5.  5.  3    |             Casetta I, et al (1996): Multiple sclerosis in Italy. A reappraisal
 87   II,     5.  5.  3    |        follow-up of the incidence of multiple sclerosis in Hordaland County,
 88   II,     5.  5.  3    |              Hansen G, et al (2000): Multiple sclerosis in North Norway,
 89   II,     5.  5.  3    |        people severely affected with multiple sclerosis. [On-line publication
 90   II,     5.  5.  3    |          Projection of the number of multiple sclerosis patients in germany].
 91   II,     5.  5.  3    |             Symptomatic Treatment of Multiple Sclerosis. Multiple Sclerosis
 92   II,     5.  5.  3    |     Treatment of Multiple Sclerosis. Multiple Sclerosis Therapy Consensus
 93   II,     5.  5.  3    |          Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol.
 94   II,     5.  5.  3    |         Horakova D (2004): Report of multiple sclerosis center at Charles
 95   II,     5.  5.  3    |               1989): Epidemiology of multiple sclerosis in Czechoslovakia.
 96   II,     5.  5.  3    |          Crimi G (eds): An Update on Multiple Sclerosis. Monduzzi Editore,
 97   II,     5.  5.  3    |               1988): Epidemiology of multiple sclerosis: incidence and
 98   II,     5.  5.  3    |          194864 based on the Danish Multiple Sclerosis Registry. Acta
 99   II,     5.  5.  3    |     Hyllested K (1992): Incidence of multiple sclerosis in Denmark 1948-
100   II,     5.  5.  3    |  Koch-Henriksen N (1999): The Danish Multiple Sclerosis Registry: a 50-
101   II,     5.  5.  3    |             et al (2001). The Danish Multiple Sclerosis Registry. History,
102   II,     5.  5.  3    |     Epidemiological investigation of multiple sclerosis in Slovenia. In:
103   II,     5.  5.  3    |          Firnhaber W, Lauer K (eds): Multiple Sclerosis in Europe: An
104   II,     5.  5.  3    |     Scheinberg LC (1988): Fatigue in multiple sclerosis. Arch Neurol 45:
105   II,     5.  5.  3    |           neurological impairment in multiple sclerosis and expanded disability
106   II,     5.  5.  3    |          Geographic disproportion of multiple sclerosis in Czechoslovakia
107   II,     5.  5.  3    |          Firnhaber W, Lauer K (eds): Multiple Sclerosis in Europe: An
108   II,     5.  5.  3    |      Defining the clinical course of multiple sclerosis: results from
109   II,     5.  5.  3    |       international survey. National Multiple Sclerosis Society (USA):
110   II,     5.  5.  3    |              Trials on New Agents in Multiple Sclerosis. Neurology 46:
111   II,     5.  5.  3    |          1996): Distinct patterns of multiple sclerosis pathology indicates
112   II,     5.  5.  3    |              diagnostic criteria for multiple sclerosis: guidelines from
113   II,     5.  5.  3    |            Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology
114   II,     5.  5.  3    |            An epidemiologic study of multiple sclerosis in Northern Ireland.
115   II,     5.  5.  3    |         study of primary progressive multiple sclerosis in Northern Ireland,
116   II,     5.  5.  3    |           disability and handicap in multiple sclerosis: a population-based
117   II,     5.  5.  3    |       variation in the prevalence of multiple sclerosis in Ireland, an
118   II,     5.  5.  3    |         Middleton LT, Dean G (1991): Multiple sclerosis in Cyprus. J Neurol
119   II,     5.  5.  3    |              N (1997): Prevalence of multiple sclerosis in Bulgaria. Neuroepidemiology
120   II,     5.  5.  3    |              Care of the person with multiple sclerosis. In: Compston
121   II,     5.  5.  3    |         Compston A. (ed). McAlpine’s Multiple sclerosis. China: Churchill
122   II,     5.  5.  3    |          prevalence and incidence of multiple sclerosis: an epidemiological
123   II,     5.  5.  3    |          Firnhaber W, Lauer K (eds): Multiple Sclerosis in Europe: An
124   II,     5.  5.  3    |             JM (1997): Prevalence of multiple sclerosis in the province
125   II,     5.  5.  3    |        Giroud M (2000): Incidence of multiple sclerosis in Dijon, France :
126   II,     5.  5.  3    |        Neurol Res 22:156-159.~MSTCG (Multiple sclerosis therapy consensus
127   II,     5.  5.  3    |          immunomodulatory therapy of multiple sclerosis. Update. Nervenarzt
128   II,     5.  5.  3    |            Article in German)~MSTCG (Multiple sclerosis therapy consensus
129   II,     5.  5.  3    |              H (2006): The Norwegian Multiple Sclerosis National Competence
130   II,     5.  5.  3    |       Competence Centre and National Multiple Sclerosis registry—a resource
131   II,     5.  5.  3    |          Prevalence and incidence of multiple sclerosis in Catania, Sicily.
132   II,     5.  5.  3    |               Weinshenker BG (2000): Multiple sclerosis. N Engl J Med
133   II,     5.  5.  3    |         persistent high frequency of multiple sclerosis in Croatia and
134   II,     5.  5.  3    |              Epidemiological data of multiple sclerosis in the province
135   II,     5.  5.  3    |              diagnostic criteria for multiple sclerosis: guidelines for
136   II,     5.  5.  3    |              Increasing incidence of multiple sclerosis in South Lower
137   II,     5.  5.  3    |               1999): Epidemiology of multiple sclerosis in the region
138   II,     5.  5.  3    |           Epidemiological aspects of multiple sclerosis: a comparative
139   II,     5.  5.  3    |              Solinas G et al (2001): Multiple sclerosis epidemiology in
140   II,     5.  5.  3    |              Increasing incidence of multiple sclerosis in the province
141   II,     5.  5.  3    |           2006): The epidemiology of multiple sclerosis in Europe. Eur
142   II,     5.  5.  3    |              press): Epidemiology of multiple sclerosis. In: Raine CS,
143   II,     5.  5.  3    |      McFarland HF, Hohlfeld H (eds). Multiple sclerosis. A comprehensive
144   II,     5.  5.  3    |              Increasing frequency of multiple sclerosis in Padova, Italy:
145   II,     5.  5.  3    |              M, Compston DAS (1995): multiple sclerosis in the North Cambridgeshire
146   II,     5.  5.  3    |            the clinical diagnosis of multiple sclerosis. Neurology 26:
147   II,     5.  5.  3    |          incidence and prevalence of multiple sclerosis in South East
148   II,     5.  5.  3    |               1993): Epidemiology of multiple sclerosis: a critical overview.
149   II,     5.  5.  3    |             al (2004): Occurrence of multiple sclerosis in central Finland:
150   II,     5.  5.  3    |        variation in the incidence of multiple sclerosis in Finland 1979-
151   II,     5.  5.  3    |             Increasing prevalence of multiple sclerosis in Finland. Acta
152   II,     5.  5.  3    |         Hakama M, Wikström J (2003): Multiple sclerosis in Finland: incidence
153   II,     5.  5.  3    |              L (2001): Prevalence of multiple sclerosis in Västerbotten
154   II,     5.  5.  3    |            and prevalence (1997): of multiple sclerosis in Västerbotten
155   II,     5.  5.  3    |          Clinical characteristics of multiple sclerosis in Västerbotten
156   II,     5.  5.  3    |              R (1999): Prevalence of multiple sclerosis in Valladolid,
157   II,     5.  5.  3    |             al (2000): Prevalence of multiple sclerosis in the L’Aquila
158   II,     5.  5.  3    |        transection in the lesions of multiple sclerosis. N Engl J Med
159   II,     5.  5.  3    |          International Federation of Multiple Sclerosis) [on line publication
160   II,     5.  5.  3    |              H (1994): Prevalence of multiple sclerosis in Flanders, Belgium.
161   II,     5.  5.  3    |      variations in the prevalence of multiple sclerosis in French farmers.
162   II,     5.  5.  3    |           epidemiological studies on multiple sclerosis. Neuroepidemiology
163   II,     5.  5.  3    |             CDMS~Clinically Definite Multiple Sclerosis~CPMS~Clinically
164   II,     5.  5.  3    |             CPMS~Clinically Probable Multiple Sclerosis~CP-MS~Chronic
165   II,     5.  5.  3    |            CP-MS~Chronic Progressive Multiple Sclerosis~CNS~Central Nervous
166   II,     5.  5.  3    |      Adjusted Life Years~DMSR~Danish Multiple Sclerosis Registry~EDSS~
167   II,     5.  5.  3    |         Medical Agency~EMSP~European Multiple Sclerosis Platform~EU~European
168   II,     5.  5.  3    |        Laboratory-Supported Definite Multiple Sclerosis~LSPMS~Laboratory-Supported
169   II,     5.  5.  3    |        Laboratory-Supported Probable Multiple Sclerosis~MRI~Magnetic Resonance
170   II,     5.  5.  3    |        Magnetic Resonance Imaging~MS~Multiple Sclerosis~MS-ID~Multiple
171   II,     5.  5.  3    |             Multiple Sclerosis~MS-ID~Multiple Sclerosis Information Dividend~
172   II,     5.  5.  3    |            Information Dividend~MSIF~Multiple Sclerosis International
173   II,     5.  5.  3    |       International Federation~MSTCG~Multiple Sclerosis Therapy Consensus
174   II,     5.  5.  3    |            PP-MS~Primary Progressive Multiple Sclerosis~PR-MS~Progressive-Relapsing
175   II,     5.  5.  3    |          PR-MS~Progressive-Relapsing Multiple Sclerosis~RR-MS~Relapsing-Remitting
176   II,     5.  5.  3    |            RR-MS~Relapsing-Remitting Multiple Sclerosis~SC~Subcutaneously~
177   II,     5.  5.  3    |          SP-MS~Secondary Progressive Multiple Sclerosis~UK~United Kingdom~
178   II,     5.  5.  3    |       typical symptoms of PD include multiple system atrophy (MSA), progressive
179   II,     5.  5.  3    |       Rybicki BA, Johnson CC (2004): Multiple risk factors for Parkinson180   II,     5.  5.  3    |          Epidemiological evidence on multiple system atrophy. J Neural
181   II,     5.  8.  3    |             patients frequently have multiple chronic health conditions.
182   II,     5.  8.  3    |             deaths from COPD and the multiple underlying causes (Furhman
183   II,     5.  8.  7    |              in France, 1979-2002: a multiple cause analysis. Thorax 2006;
184   II,     5.  8.  7    |         disease patients die from? A multiple cause coding analysis. Eur
185   II,     5.  9.  4    |    phenomenon is probably related to multiple genetic and environmental
186   II,     5.  9.  4    |        females (P=0.03). Analysis by multiple logistic regression showed
187   II,     6.  3.  3    |          such as IDU and people with multiple sex partners.~ ~Almost 180
188   II,     7.  4.  2    |      muscular strengths, revision of multiple medication). . Existing
189   II,     8.  2.  1    |        disability is currently used. Multiple terms give rise to some
190   II,     8.  2.  1    |         emerging perspective is that multiple and complex factors associated
191   II,     9            |            1993; Huang et al, 2000). Multiple pregnancies also carry a
192   II,     9            |         higher preterm birth rate in multiple pregnancies (Ananth et al,
193   II,     9            |              to be an interaction of multiple environmental and genetic
194   II,     9            |         factors for STIs can include multiple sex partners and a weakened
195   II,     9.  1.  1    |      characteristics/Risk factors~C: Multiple birth rate by number of
196   II,     9.  1.  1    |             2006): Preterm birth and multiple pregnancy in European countries
197   II,     9.  1.  1    |             Magee BD (2004): Role of multiple births in very low birth weight
198   II,     9.  1.  2    |             anomaly registers, using multiple sources of information to
199   II,     9.  1.  2    |            1993; Huang et al, 2000). Multiple pregnancies also carry a
200   II,     9.  1.  2    |         higher preterm birth rate in multiple pregnancies (Ananth et al,
201   II,     9.  1.  2    |              to be an interaction of multiple environmental and genetic
202   II,     9.  2.  4    |         factors for STIs can include multiple sex partners and a weakened
203   II,     9.  3.  1    |            fundamental in menopause. Multiple population-based studies
204   II,     9.  3.  2    |      maternal conditions, the higher multiple birth rates caused by more
205   II,     9.  3.  2    |             monitored, including the multiple birth rate, maternal age,
206   II,     9.  3.  2    |            these treatments increase multiple births – which have higher
207   II,     9.  3.  2    |             2006): Preterm birth and multiple pregnancy in European countries
208   II,     9.  3.  2    |             Magee BD (2004): Role of multiple births in very low birth weight
209   II,     9.  3.  3    |          such as occasional sex with multiple partners without use of
210   II,     9.  3.  3    |           for example, definition of multiple partners in the countries
211   II,     9.  3.  3    |         Besides higher prevalence of multiple partners, men also report
212   II,     9.  3.  3    |        notice a higher prevalence of multiple partners than the Finnish
213   II,     9.  4.  5    |       pathology - the other 84% have multiple illnesses and/or rehabilitation
214   II,     9.  4.  5    |        mostly due to the presence of multiple conditions (co-morbidities).
215   II,     9.  5.  1    |              consider a lifespan and multiple role perspective.~ ~Gender-specific
216   II,     9.  5.  3    |            and the administration of multiple prescription medication.
217  III,    10.  1        |              combined exposures from multiple sources (food, air and water),
218  III,    10.  1        |           extreme weather conditions~Multiple exposures~Leisure areas~
219  III,    10.  1        |       Increased chemical sensitivity~multiple chemical exposures at low
220  III,    10.  2.  1    |              data are collected from multiple sources by the Tobacco or
221  III,    10.  2.  1    |            use started to grow among multiple groups, including problem
222  III,    10.  2.  1    |           also often use cocaine and multiple other substances, marginalized
223  III,    10.  2.  1    | characterized by poly-drug use where multiple illicit and licit substances
224  III,    10.  2.  1    |          problem drug users presents multiple health problems, including
225  III,    10.  2.  4    |          with smoking on the risk of multiple myeloma, coronary heart
226  III,    10.  2.  4    |              concurrent detection of multiple genomic variants that have
227  III,    10.  2.  4    |           will be possible to assess multiple genomic and protein differences
228  III,    10.  3.  2    |       Increased chemical sensitivity~multiple chemical exposures at low
229  III,    10.  3.  4    |            are further aggravated by multiple stresses. Although there
230  III,    10.  4.  2    |         expected effect. Exposure to multiple residues of pesticides via
231  III,    10.  4.  5    |                              10.4.5. Multiple exposure: bathing water
232  III,    10.  4.  5    |           provides opportunities for multiple exposure of human beings
233  III,    10.  5.  3    |           are flexibly deployed over multiple tasks. Some contractual
234  III,    10.  5.  3    |    institutions.~Diseases often have multiple causes. They are associated
235  III,    10.  5.  3    |             Diseases most often have multiple causes. They are associated
236   IV,    11.  1.  3    |        performance data results from multiple influences. On the supply
237   IV,    11.  1.  5    |             2003). Patients who face multiple interventions and have more
238   IV,    11.  5.  4    |         organ donation can be due to multiple factors, including pressure
239   IV,    11.  6.  2    |         disadvantages. For instance, multiple funds that can compete may
240   IV,    11.  6.  2    |         perspective. Where there are multiple competing funds, as in the
241   IV,    11.  6.  2    |           heavily on the presence of multiple funds, the insurance market
242   IV,    11.  6.  4    |             in cases where there are multiple collection agents as in
243   IV,    12.  5        |              objectives are built on multiple lines (Table 12.9).~ ~Table
244   IV,    12. 10        |       policies and services to which multiple categories of groups-excluded
245   IV,    13.  2.  2    |            DALYs. The total DALY for Multiple Sclerosis in Europe is 307
246   IV,    13.  5        |        higher risk of suffering from multiple co-morbidities and experiencing